Both are wrestling with slowing sales and, shall we say, a persistent lack of profitability. Throw in rising interest rates, and their valuations have taken a hit. Now, as someone who likes a good dividend (and let’s be real, these aren’t paying dividends anytime soon), I’m always looking for a turnaround story. But is either of these companies a worthwhile gamble, or are we just throwing good money after bad? Let’s dig in, because I need a distraction from my 401k.
For a considerable period, Intel enjoyed a position of unchallenged leadership, a circumstance which, while enviable, often breeds a certain complacency. However, the tides of innovation, as they are wont to do, have shifted, and Taiwan Semiconductor, or TSMC as it is more familiarly known, now occupies a most advantageous position. To declare, therefore, that a consideration of TSMC is the more sensible course for an investment in 2026, is not to disparage Intel, but merely to acknowledge the present disposition of the field.
So, let’s dive back down the rabbit hole. Can Polkadot claw its way out of this mess? Is there anything left of the dream, or is it just another beautiful, broken promise in the crypto wasteland? I’ve been staring at the charts, the white papers, the breathless pronouncements of the true believers…and frankly, it feels like trying to assemble a jigsaw puzzle while riding a bucking bronco.
The Government of Bermuda, in a bold move that would make even the most jaded Victorian explorer weep into his brandy, has partnered with Coinbase and Circle to “move large parts of its national economy onchain.” This, they claim, is not a metaphor. One imagines a scene where bureaucrats, armed with smartphones instead of quills, solemnly declare, “The future is blockchain!” while seagulls squawk in the background.
It seems investors, distracted by the shiny objects and breathless pronouncements of the Tesla acolytes, almost overlooked the fact that Ford actually moved some metal in 2025. A genuine, old-fashioned, internal-combustion-powered accomplishment. It’s like discovering your grandfather still knows how to whittle. Quaint, I suppose.
The stock, having ascended to heights that would make Icarus blush – a thousand percent increase since the AI fever truly took hold – now finds itself in a curious state. A temporary inconvenience, perhaps? Or the first tremor before a more substantial collapse? The market, that fickle beast, is offering a discount. A most intriguing development. It suggests a lack of faith, a suspicion that the golden age is waning. But history, as I’ve learned in my years poring over dusty ledgers and forgotten balance sheets, rarely operates on simple logic.
GE Vernova, if you’re keeping track – and honestly, who isn’t these days? – is one of the offspring of the General Electric empire. They’ve decided to specialize, which, in the business world, is a bit like deciding to only collect stamps featuring aardvarks. It narrows the focus. They’ve got three main lines of business: power generation, wind energy, and, rather broadly, ‘electrification.’ The wind side is… well, let’s say it’s undergoing a period of strategic adjustment. But the power and electrification bits? Those are positively humming.
SoundHound. It’s all about voices, apparently. Which is ironic, because I’ve been mostly silent since realizing how much money I lost on Dogecoin. They make apps that recognize voices. I mostly just yell at my smart speaker when it misinterprets my requests. But apparently, this is a big deal. They’re working with car companies, restaurants… even Mastercard. It’s all very… corporate. They seem to be acquiring smaller companies, which is a good sign, I think. Like a sensible adult, rather than a frantic magpie collecting shiny things. Analysts predict revenue growth of 30% CAGR. Which sounds… promising. It’s a bit pricey, though. $4.5 billion valuation. Still, maybe it’s worth the risk. I mean, what’s a few more sleepless nights when you’re already questioning all your life choices?
Everyone’s terribly excited about this Tyler Radke at Citi, upgrading his outlook. $235 price target. Thirty-four percent upside. Oh, fantastic. Another analyst throwing fuel onto the bonfire. It’s almost… endearing. Like watching someone desperately try to convince themselves they’ve made a good decision. I mean, I’ve been that person. Several times. Usually involving shoes.
Ulcerative colitis. Right. Another crowded market. Everyone’s got a pill for something these days. And they all suppress your immune system. That’s the trick, isn’t it? Fix one thing, break three others. It’s like rearranging furniture to make more space, and then realizing you’ve blocked the doorway. Obefazimod supposedly doesn’t do that. It’s different. It’s…gentle. Of course, they say that. They have to. The phase 3 trial showed remission. Statistically significant. Wonderful. And nearly half the patients had already tried other things. So, they’re the ones the other drugs didn’t work on. That’s… convenient. It’s like saying your new vacuum cleaner works great on dirt that other vacuums couldn’t pick up. It doesn’t exactly inspire confidence. Blockbuster potential, they say. I just… I don’t buy it. It’s just a word. A marketing term.